Adjunct to diet for reduction of elevated total-cholesterol, LDL-cholesterol, apolipoprotein B, & triglycerides in patients w/ primary hypercholesterolaemia (heterozygous familial & non familial) & mixed dyslipidemia. Adjunct to diet for the treatment of patients w/ elevated serum triglyceride levels. Adjunct to lipid lowering treatment in patients w/ homozygous familial hypercholesterolaemia.
Perform liver function tests prior to & at 12 wk following initiation of therapy & dose elevation. Reduce dose or discontinue therapy if increase in ALT levels >3 times the upper limit of normal persists. Alcoholics or patients w/ history of liver disease. Skeletal muscle effects; rhabdomyolysis w/ acute renal failure secondary to myoglobinuria has been reported w/ other drugs of this class. Discontinue therapy in cases of marked elevated CPK levels or diagnosed or suspected myopathy, or w/ a risk factor predisposing to development of renal failure secondary to rhabdomyolysis (eg, hypotension, major surgery, trauma, severe metabolic, endocrine & electrolyte disorders & uncontrolled seizures). Hepatic insufficiency.